| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3906392 | Urology | 2007 | 6 Pages |
Abstract
For patients with intermediate-risk prostate cancer, brachytherapy-based treatment and the addition of AD to SD-EBRT resulted in improved biochemical outcomes compared with the outcomes with SD-EBRT alone; however, these findings were dependent on the definition of biochemical failure used. The year of treatment may be an important prognostic factor in intermediate-risk prostate cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Vinai Gondi, Israel Deutsch, Mahesh Mansukhani, Kathleen M. O'Toole, Jinesh N. Shah, Peter B. Schiff, Aaron E. Katz, Mitchell C. Benson, Erik T. Goluboff, Ronald D. Ennis,